Sorafenib, Sunitinib Fail in Phase III Adjuvant RCC Trial
February 23rd 2015Neither sorafenib nor sunitinib improved outcomes when administered after surgery to patients with locally advanced renal cell carcinoma (RCC), according to results from the phase III ASSURE trial, which were presented at a presscast held ahead of the 2015 Genitourinary Cancers Symposium.
Read More
Sequencing Therapies in Follicular Lymphoma Requires Multifaceted Approach
February 20th 2015The indolent nature of follicular lymphoma and the range of treatment options currently available or in development may create complicated questions regarding how to best use and sequence these therapies.
Read More
Immunotherapy, Personalized Medicine to Highlight Winter Hematology Meeting
February 20th 2015Oncologists, hematologists, and other experts on hematologic malignancies will convene for the 19th Annual International Congress on Hematologic Malignancies, from February 20-21 in Miami, Florida, to provide insight into recent developments in the treatment of the diseases.
Read More
First Oral Proteasome Inhibitor Meets PFS Endpoint in Phase III Myeloma Trial
February 11th 2015The proteasome inhibitor ixazomib met its primary endpoint of improving progression-free survival at a prespecified interim analysis of a phase III trial of patients with relapsed/refractory multiple myeloma.
Read More
More Positive Data for BRAF/MEK Combo in Melanoma, But Debate Continues
January 29th 2015The combination of trametinib (Mekinist) and dabrafenib (Tafinlar) improved overall survival (OS) compared with vemurafenib alone in patients with unresectable (stage IIIC) or metastatic (stage IV) BRAFV600E/K mutation-positive cutaneous melanoma.
Read More
Expert Discusses Integration of PD-1 Inhibitors Into Clinical Practice
January 13th 2015To gain insight on the integration of these agents and other immunotherapies into clinical practice, OncLive interviewed Jeffery S. Weber, MD, PhD, a senior member at Moffitt Cancer Center in Tampa, Florida.
Read More
FDA Approves Ramucirumab for NSCLC
December 12th 2014The FDA has approved the VEGFR-2 inhibitor ramucirumab (Cyramza) in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumor has progressed during or following treatment with platinum-based chemotherapy.
Read More
Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL
December 8th 2014Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.
Read More
CAR Therapy Demonstrates Promise in ALL
October 17th 2014The investigational chimeric antigen receptor (CAR) therapy CTL019 demonstrated promising activity in 2 pilot trials, eliciting complete remissions in 27 of 30 pediatric and adult patients (90%) with relapsed/refractory acute lymphoblastic leukemia (ALL).
Read More
NCI Awards $1.4 Million Grant to Develop Test for B-Cell NHLs
October 14th 2014Advanced Cell Diagnostics, Inc. (ACD) and Cleveland Clinic were jointly awarded a 2-year, $1.4 million grant from the National Cancer Institute (NCI) to develop and validate a diagnostic test to identify B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.
Read More
Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents
October 4th 2014Androgen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to AR-targeting agents, such as abiraterone or enzalutamide.
Read More
Infinity Inks Deals to Expand Research Into Duvelisib
September 23rd 2014Infinity Pharmaceuticals has entered into two separate agreements with Roche and AbbVie to develop and commercialize duvelisib (IPI-145), an oral inhibitor of PI3K-delta and PI3K-gamma, for the treatment of patients with hematologic malignancies.
Read More